Endometrial angiogenesis is not well studied, but has potential as a model for studies of physiological angiogenesis. Migration as well as proliferation of vascular endothelial cells are modulated by other endometrial cells. This study analyzes the chemotactic signal released from endometrial tissue in a wound assay using human microvascular endothelial cells. Endometrial tissue explants stimulate migration, and this effect is significantly weaker with explants taken at midcycle than those obtained earlier or later in the cycle. Migration is inhibited more than 50% by either blocking antibodies to the urokinase plasminogen activator receptor (uPAR) or enzymatic removal of uPAR from the cell surface. Also, migration is inhibited more than 50% by antibodies to epidermal growth factor (EGF), but not by antibodies to vascular endothelial growth factor or basic fibroblast growth factor. The combination of anti-EGF and anti-uPAR antibodies does not further reduce the response, suggesting that these antibodies target a common pathway. Conditioned medium from endometrial explants contains EGF, and EGF stimulates the migration of endothelial cells in a dose-dependent way. This effect is completely blocked by antibodies to uPAR. These data suggest up-regulation of the uPA system by EGF. Conditioned medium from EGF-treated cells contains less uPA than medium from control cells. In contrast, binding of radiolabeled uPA reveals an increased number of uPA-binding sites in EGF-treated cells. Increased expression of uPAR potentially increases the activation and assembly of focal adhesion sites, a prerequisite for cell migration. We conclude that the endometrial migratory signal has two components. The major part of the signal is blocked by antibodies to EGF, and the response is mediated via upregulation of uPAR in the endothelial cells. The other part of the signal is unknown, and the response does not involve uPAR. Decreased endometrial chemotactic signal at midcycle is probably related to decreased release of EGF, which is secondary to increased binding to endometrial cell membranes. (J Clin Endocrinol Metab 86: 1724 -1730, 2001) 
metrial explants contains EGF, and EGF stimulates the migration of endothelial cells in a dose-dependent way. This effect is completely blocked by antibodies to uPAR. These data suggest up-regulation of the uPA system by EGF. Conditioned medium from EGF-treated cells contains less uPA than medium from control cells. In contrast, binding of radiolabeled uPA reveals an increased number of uPA-binding sites in EGF-treated cells. Increased expression of uPAR potentially increases the activation and assembly of focal adhesion sites, a prerequisite for cell migration. We conclude that the endometrial migratory signal has two components. The major part of the signal is blocked by antibodies to EGF, and the response is mediated via upregulation of uPAR in the endothelial cells. The other part of the signal is unknown, and the response does not involve uPAR. Decreased endometrial chemotactic signal at midcycle is probably related to decreased release of EGF, which is secondary to increased binding to endometrial cell membranes. (J Clin Endocrinol Metab 86: 1724 -1730, 2001) E NDOMETRIAL TISSUE is exceptional in the adult organism, because it displays physiological angiogenesis. The rapid regeneration of endometrial tissue after menstrual shedding requires concomitant recruitment of vasculature to support the growing tissue. This angiogenic process involves both proliferation and migration of vascular endothelial cells. Endometrial angiogenesis is, however, not well studied, but extensive studies of angiogenesis have been carried out in other processes, e.g. malignant tumor growth, embryogenesis, wound healing, etc. A general concept that derives from these studies is that the vasculature expands in response to signaling from the growing tissue. Several signal molecules have been identified, and some of these occur in human endometrial tissue, e.g. vascular endothelial growth factor (VEGF), which is present in several splice variants (1); members of the fibroblast growth factor family, most notably basic fibroblast growth factor (bFGF) (2); transforming growth factor-␤ (3); platelet-derived endothelial cell growth factor (4); and epidermal growth factor (EGF) (5, 6) .
Cell migration, i.e. the locomotion of a cell over a substratum, involves extension of the cell at the leading edge and retraction at the trailing edge. Focal adhesion sites function as the transition between cytoplasmic actin fibrils and the extracellular matrix. During migration the urokinase plasminogen activator receptor (uPAR) is located at focal adhesion sites in the leading edge of the cell, and activation of uPAR by ligand binding initiates assembly of focal adhesion proteins involving integrin receptors, vitronectin, caveolin, p130 cas , and focal adhesion kinase (7) (8) (9) . We have previously shown that endometrial tissue explants as well as separated stromal and glandular epithelial cells in culture release uPA, and that human microvascular and umbilical vein endothelial cells migrate in response to uPA (10 -14) . Our data, furthermore, demonstrated that the catalytic site of uPA was not required, as uPA in complex with plasminogen activator inhibitor-1 was equally efficient to stimulate cell migration. In contrast, binding of uPA to uPAR was critical, because interference with this interaction inhibited the migratory response. The present study of microvascular endothelial cells aimed to characterize the chemotactic signal released from endometrial tissue with respect to cyclic variation, molecular nature, and mechanism of action.
Materials and Methods

Tissue processing
Endometrial tissue was obtained from uteri removed for benign nonendometrial pathology, i.e. cervical dysplasia, dysmenorrhea, uterine prolapsus, adenomyosis, and fibromyomas. All patients were parous, 30 -45 yr of age, and had regular menstrual cycles. None used oral contraceptives or hormone replacement therapy. Permission to use part of the endometrium was granted by the university review board for studies on human subjects. The endometrial samples were gently scraped off the upper part of the uterine cavity immediately after removal of the uteri and were transferred to the laboratory in sterile Hanks' Balanced Salt Solution (HBSS). Endometrial pathology was excluded by the histopathological examination. All endometrial samples were classified with respect to the phase of the menstrual cycle (15, 16) . The proliferative phase was subdivided into early (days 5-7), mid (days 8 -10), and late (days [11] [12] [13] [14] stages, and the secretory phase was similarly divided into early (days [15] [16] [17] [18] [19] , mid (days 20 -22) , and late (days [23] [24] [25] [26] [27] [28] stages. The late proliferative and early secretory stages were subsequently included in the midcycle phase. Unless specified, endometrial tissue samples used in the experiments were obtained in the proliferative, midcycle, and secretory phases.
Endothelial cell culture
A human microvascular endothelial cell line (HMEC-1) was obtained from CDC (Atlanta, GA). These cells were grown on uncoated plastic in medium MCDB 131 supplemented with EGF (10 ng/mL), hydrocortisone (1 g/mL), and 15% FBS. Some experiments were also performed with two additional endothelial cell types, HUVEC and ECV-304. HUVEC, obtained from human umbilical cords as we previously described (14) , were cultured in plates coated with 0.1% gelatin in medium 199 supplemented with 20% FBS. ECV 304, a spontaneously transformed immortal human endothelial cell line obtained from American Type Culture Collection (Manassas, VA), were grown on uncoated plastic in medium 199 supplemented with 10% FBS. All endothelial cells were grown in six-well tissue culture plates at 37 C in 5% CO 2 -95% air.
Wound assay
At confluence a wound was made by pressing a razor blade through the cell sheet and gently scraping off the cells, essentially as described by Sato and Rifkin with modifications (14, 17) . The cultures were rinsed with HBSS to eliminate debris, and medium without supplements was added. Culture medium and HBSS were phenol red free. Explants (1-mm 3 pieces) of endometrial tissue (50 mg/well) were added to the denuded area, i.e. not in physical contact with the endothelial cells, and the wounded cultures were subsequently incubated for 24 h. The cultures were then fixed in absolute methanol for 5 min and stained with 12% Giemsa for 15 min. The number of cells that had migrated across the wound line was counted in four to six high power fields in each well, and the mean was taken as the result. Migration in stimulated wells was subsequently calculated as a percentage of that in unstimulated wells of the same experiment. Wound repair assays, like that described here, have been shown not to be affected by variations in cell proliferation (18, 19) . The design of the migratory assay allowed us to study the effect of signal molecules released in serum-free medium from endometrial tissue explants and affecting microvascular endothelial cells, which were not in contact with the explants. By using the same amount of endometrial tissue (50 mg) in all experiments, the response could be quantitatively related to the cyclic phase of the explants. EGF, bFGF, VEGF, phosphatidyl inositol-specific phospholipase C (PiPLC), and monoclonal antibodies to EGF, VEGF, and bFGF were obtained from Sigma (St. Louis, MO), and Aspergillus niger (control antibody) was purchased from Dakopatts (Copenhagen, Denmark). Blocking monoclonal antibody to uPAR, R3, was a gift from Dr. G. Høyer-Hansen (Finsenlab, Copenhagen, Denmark) (20) .
Assay for EGF and uPA
The concentrations of EGF in conditioned medium were measured with a commercial enzyme-linked immunosorbent assay (ELISA; Quantikine EGF immunoassay kit, R&D Systems, Inc., Abingdon, UK). This is a solid phase ELISA that uses a monoclonal catching antibody and a horseradish peroxidase-linked polyclonal detecting antibody. We used 3.1 pg/mL as the detection limit. The intraassay variation was 3%, and the interassay variation was 5%. Conditioned medium concentrations of uPA were assayed with a commercial TintElize uPA (Biopool, Umea, Sweden). The assay has two monoclonal catching antibodies and a horseradish peroxidase-polyclonal antibody conjugate detection system. It includes a system for internal subtraction of nonspecific signal. The ELISA measured the single chain form and the high molecular weight form of uPA with high efficiency. The low molecular weight form of uPA was measured with about 40% efficiency. The detection limit was 0.1 ng/mL. At 0.7 ng/mL, the intraassay variation was 10%.
Purification and radiolabeling of uPA uPA was purified from Ukidan (Serono, Geneva, Switzerland) by affinity chromatography on a benzamidine-Sepharose column as previously described (12) . The active enzyme fraction was further separated in high (50 kDa) and low (33 kDa) molecular mass fractions by gel filtration on Sephadex G-100. The peak fraction of high molecular mass uPA, which was 98 -99% pure in immunoblotting, was used for 125 I labeling with the lactoperoxidase method. Specific radioactivity ranged from 0.4 -0.6 megabecquerels/g protein.
Assay of [ 125 I]uPA binding to HMEC-1 cultures
Confluent cultures were given serum-free medium and stimulated with EGF (10 ng/mL) or HBSS as a control for 24 h at 37 C before being incubated on ice for 2 h with radiolabeled uPA in HBSS containing BSA (10 g/L). After removal of the experimental buffer, cells were washed six times with ice-cold HBSS and subsequently lysed with NaOH (1 mol/L). The radioactivity of the lysate was counted in a 1260 Multigamma counter (Pharmacia Biotech, Uppsala, Sweden). Nonspecific binding was assayed with the same procedure, but in the presence of a 100-fold molar excess of unlabeled uPA, and specific binding was calculated as the difference between total and nonspecific binding. To measure the total number of receptors, endogenously bound uPA was removed by briefly (2-3 min) exposing the cells to 75 mmol/L acetate buffer, pH 3.0, containing 2.5 mmol/L CaCl 2 , 0.5 mmol/L MgCl 2 , and 0.3 mol/L NaCl, and then rinsed four times with ice-cold HBSS before the incubation with radiolabeled uPA. The number of occupied receptors was calculated as the difference between the numbers of total and free receptors.
Statistical methods
Results were expressed either as the median and percentile or as the mean Ϯ se. Differences between groups were tested for significance using Wilcoxon signed rank test for paired comparison and MannWhitney U test for nonpaired comparison.
Results
Endometrial tissue samples obtained at midcycle had significantly weaker chemotactic signal than samples taken earlier in the proliferative phase or later in the secretory phase (Fig. 1) . Incubation of the endometrial explants with estradiol for 24 h before the wound assay increased the chemotactic signal, whereas preincubation with progesterone alone resulted in a slight reduction (Fig. 2) . This negative effect of progesterone was, however, reversed by the presence of estradiol.
We have previously shown that uPA is chemotactic for both HMEC-1 and umbilical vein endothelial cells (14) and that uPA is released from endometrial tissue and separated endometrial cells (10, 12, 13) . We therefore examined the possibility that the migratory response was related to the uPA system. A monoclonal antibody, which has affinity for an epitope in domains 1 and 2 of uPAR and blocks the binding site for uPA by a noncompetitive inhibitory mechanism (20) , completely inhibited the migratory response to 1 nmol/L uPA in HMEC-1 (Fig. 3) . Also, this antibody blocked about half the stimulatory effect of endometrial tissue explants, suggesting that the endometrial migratory signal has at least two components, one that engages the uPA system and one that does not. In an additional experiment we performed the cell migration assay with endometrial explants in the presence of PiPLC, which efficiently cleaves the phosphatidyl inositol anchor of uPAR and thus depletes the cell surface of uPAR. Treatment with PiPLC resulted in more than 50% reduction of the endometrial stimulation (not shown). These results suggest that the major part of the response to endometrial tissue in HMEC-1 was mediated by uPAR.
The concentration of uPA in the conditioned medium from 12 endometrial explant cultures (without HMEC-1) using the same amount of tissue, i.e. 50 mg, and the same volume of medium as in the migration assay was 5.2 Ϯ 0.8 ng/mL (not shown). This corresponds roughly to 0.1 nmol/L, which gives submaximal stimulation of HMEC-1 migration (14) . This low release of uPA from endometrial explants may have contributed to the migratory signal, but cannot by itself account for the impressive increase in migration seen in many experiments. Pure cultures of HMEC-1 also released uPA to the medium in similar concentration (6.7 Ϯ 0.7 ng/mL; not shown), and this may explain the minute, but significant, reduction of basal migration found with the antibody to uPAR.
Several growth factors that are known to be present in the endometrium have effects on endothelial cells. Thus, we performed the migratory assay with endometrial tissue explants in the presence of antibodies to VEGF, bFGF, and EGF. The results show that antibodies to EGF, but not antibodies to bFGF, VEGF, or control monoclonal antibodies, reduced HMEC-1 migration by more than 50% (Fig. 4) . This finding suggests that EGF is involved in the migratory signal released from endometrial tissue. To make sure that this effect of the explants was not specific to HMEC-1, we performed the wound assay with HUVEC in the presence of explants. Migration was increased to 203 Ϯ 28% (n ϭ 5; P ϭ 0.04) of the control value in the presence of explants and was reduced to 158 Ϯ 14% (n ϭ 5; P ϭ 0.04) by the concomitant presence of anti-EGF antibodies (not shown). To verify that EGF was actually released from endometrial tissue, we analyzed 24-h conditioned medium from 21 endometrial tissue explant cultures, again using the same amount of tissue as in the migratory assay, i.e. 50 mg. The release of EGF tended to be FIG. 1. HMEC-1 migration was assayed in the absence (100%) and the presence of endometrial tissue explants. Endometrial tissue explants were classified as belonging to the proliferative (early to mid proliferative; n ϭ 8), midcycle (late proliferative to early secretory; n ϭ 5), or secretory (mid to late secretory; n ϭ 8) phase. All experiments were performed in triplicate. Migration was stimulated by the explants in all experiments compared with the control (P Ͻ 0.001). The chemotactic signal was weaker from explants obtained in the midcycle phase than from explants taken in both the proliferative (P ϭ 0.01) and secretory (P ϭ 0.003) phases.
FIG. 2.
Endometrial tissue explants taken in the proliferative phase were stimulated with dimethylsulfoxide (EX), 1 nmol/L estradiol (E-EX), 100 nmol/L progesterone (P-EX), or the combination of estradiol and progesterone (EP-EX) for 24 h before being used in the wound assay and compared with migration in HMEC-1 without explants (C; n ϭ 9). Compared with DMSO-treated explants, those pretreated with estradiol (P ϭ 0.02) and estradiol plus progesterone (P ϭ 0.008) had increased migratory signal, whereas those pretreated with progesterone had decreased migratory signal (P ϭ 0.05).
FIG. 3.
The presence of antibodies to uPAR (10 g/mL) during HMEC-1 migration blocked about half the stimulatory effect of endometrial tissue explants (EX; n ϭ 9; P ϭ 0.008). Migration stimulated by u-PA (1 nmol/L) was completely blocked by antibodies to uPAR. Also, basal migration (control) was reduced by antibodies to uPAR (P ϭ 0.02).
lower at midcycle than earlier in the proliferative phase and later in the secretory phase (Fig. 5) . We also found that the conditioned medium concentration of EGF was higher in three explant cultures that had been stimulated with 1 nmol/L estradiol than in control cultures (not shown). Four cultures had EGF levels below the detection limit and did not respond to estradiol. Two of the nonresponding cultures, but none of the responding cultures, were obtained in the midcycle phase. Conditioned media from HMEC-1 cultures had no detectable EGF.
To demonstrate that this finding did not reflect a selective sensitivity of HMEC-1 to EGF, we stimulated these cells with bFGF (10 ng/mL) and VEGF (10 ng/mL). Both of these agents increased migration to a similar extent as EGF, and the response to both of them was inhibited by antibodies to uPAR (not shown).
Next, we studied the effect of EGF on the endothelial cells and analyzed the interaction between EGF and the uPA system. EGF stimulated migration in HMEC-1, and this effect was dose dependent in the range 0.001-10 ng/mL (not shown). Migration was also stimulated by EGF in HUVEC (168 Ϯ 8% of control; n ϭ 5; P ϭ 0.04) and in ECV 304 (212 Ϯ 4% of control; n ϭ 5; P ϭ 0.04). These cells do not require EGF for growth. We subsequently stimulated HMEC-1 with 10 ng/mL EGF in the wound assay in the presence and the absence of antibodies to uPAR. The stimulatory effect of EGF on HMEC-1 migration was completely abolished by a blocking antibody to uPAR (Fig. 6 ). When the same amount of endometrial tissue was incubated with or without HMEC-1, we found in two explant cultures with detectable levels of EGF that the conditioned medium concentration of EGF was decreased in the presence of HMEC-1, suggesting that endometrial EGF is, in fact, bound to the endothelial cells. These results together suggest that endometrial EGF up-regulates the uPA system in endothelial cells, which subsequently in an autocrine mode promotes migration. To further clarify whether this was true for the migratory signal from endometrial tissue, we compared the effects of antibodies to EGF and uPAR separately and together. Each of the two antibodies by themselves was as effective as the combination in inhibiting the endometrial increase in cell migration (Fig. 7) . This suggests that EGFR and uPAR are mutually dependent actors within a common sequence of events leading to cell   FIG. 4 . The stimulatory effect of endometrial explants (EX; n ϭ 6) on HMEC-1 migration was reduced by antibodies to EGF (P ϭ 0.02), but not by antibodies to bFGF and VEGF or control antibodies to Aspergillus niger (C). All antibodies were monoclonal (MAB), and the final concentration of IgG was 1 g/mL for all.
FIG. 5. EGF was assayed in the conditioned medium of endometrial explants (50 mg/well) taken in the proliferative (n ϭ 10), midcycle (n ϭ 4), and secretory (n ϭ 7) phases. The concentration tended to be lower at midcycle than in the proliferative and secretory phases.
FIG. 6.
The migration of HMEC-1 (n ϭ 5) was stimulated by 10 ng/mL EGF (P ϭ 0.04; Ⅺ). The stimulatory effect was completely inhibited by antibodies to uPAR (P ϭ 0.04;^). Also, basal migration was reduced by antibodies to uPAR (P ϭ 0.04).
migration, and that both receptors need to be activated. To analyze plausible up-regulation of the uPA system by EGF, we assayed conditioned medium from HMEC-1 cultures for uPA and found the concentration of uPA in EGF-treated cultures to be decreased by 20 Ϯ 4% (n ϭ 6; P ϭ 0.046; not shown in the figure). We then quantitated the effect of EGF on the expression of uPAR in HMEC-1 using a radioligand binding assay. The amount of free, i.e. endogenously not occupied, receptor sites was increased by 31 Ϯ 2% after EGF treatment (n ϭ 8; P ϭ 0.01; not shown in the figure) . In contrast, the amount of occupied receptor sites was not different between EGF-treated and control cultures. Thus, the reduction of extracellular uPA in EGF-treated cultures probably results from increased receptor binding. As, however, the amount of endogenously occupied receptor sites was not increased in EGFtreated cultures it is likely that internalization and degradation of uPA were also increased. This process involves uPAR, and up-regulation of uPAR is a key event in increasing the turnover of uPA in endometrial cells (13) .
Discussion
We report that endometrial tissue released a strong signal for endothelial cell migration, and that the major part of this signal was blocked by antibodies to EGF. An antibody to uPAR inhibited the signal to a similar extent. The effect of these antibodies combined was not superior to that of each of them separately, suggesting that activations of EGFR and uPAR are mutually dependent steps in a common pathway, and that both receptors need to be activated for the migratory response to occur. Endometrial tissue explants released EGF, which bound to the endothelial cells. Also, EGF stimulated endothelial cell migration, and this effect was completely inhibited by antibodies to uPAR, further supporting the view that EGF is a signal molecule that acts through autocrine activation of the uPA system in endothelial cells. This effect seems to be general to endothelial cells, as it was not seen exclusively in HMEC-1, but was also found in HUVEC and ECV-304 cells, which do not require EGF for growth.
Migration can be stimulated in HMEC-1 by uPA via binding to and activation of uPAR (14) . In this study we found that EGF-dependent migration in these cells was also mediated via uPAR. The effect, however, did not result from increased release of uPA, but from up-regulating the number of uPAR-binding sites. As a result, an increased number of potential interactions between uPAR and integrin receptors may take place at focal adhesion sites. Migration in various cell types is reportedly dependent on up-regulated expression of either uPA or uPAR (14, (21) (22) (23) (24) (25) , and antibodies against uPA (21, 26) as well as uPA antisense oligonucleotides inhibit cell migration (27) .
Increased expression of uPAR may have several different effects, reflecting various functions of the receptor and presumably various locations on the cell surface. At focal adhesion sites an increased density of uPAR increases the number of signaling events upon activation by ligand binding, and eventually this results in increased cell migration. In addition, increased enzymatic activity of receptor-bound uPA generates more plasmin for extracellular proteolysis, which is required during the invasive process (28) . However, uPAR has yet another function. The turnover of uPA involves internalization of the enzyme bound to uPAR, a process mediated by members of the low density lipoprotein receptor family at clathrin-coated pits (28) . Up-regulation of uPAR increases internalization and degradation of uPA, and this is, in fact, the mechanism by which endometrial cells decrease uPA activity in response to progesterone (13, 29) . Apparently, the increased expression of uPAR in HMEC-1 stimulated with EGF resulted in increased internalization and degradation of uPA, as we found a decreased concentration of uPA in the conditioned medium and no increase in cell-bound uPA.
As the effect of antibodies to EGF and uPAR combined was not superior to the effect of each of them separately, we suggest that activations of EGFR and uPAR are successive events along the pathway leading to cell migration, and that activation of both is necessary for any response to occur. It has been shown that the full effect of growth factor receptor signaling requires activation and assembly of proteins at focal adhesion sites, as extracellular matrix contact is required by some adherent cells to allow growth factor-stimulated signaling through the mitogen-activated protein kinase pathway (30, 31 ). An additional possibility may be a requirement for complex formation between activated tyrosine kinase receptors and other receptors, as has been reported for platelet-derived growth factor receptor and ␣ v ␤ 3 integrin and for EGF receptor (EGFR) and G protein-linked receptors (32, 33) . We found that ligand activation of EGFR resulted in up-regulation of uPAR, which is an integral part of focal adhesion sites. Furthermore, when uPAR was blocked by antibodies and could not be activated, there was no migratory response to EGF. Thus, our observations are fully compatible with the above reports and further support FIG. 7 . The effect of antibodies to EGF and uPAR on the migratory signal from endometrial explants (EX) was studied in wounded HMEC-1 cultures (n ϭ 2). More than half of the migratory signal was blocked by either of the antibodies alone, and there was no additive effect when the two antibodies were combined. a key role for focal adhesion site activation and assembly in the process of endothelial cell migration in response to EGF.
The mechanism by which EGF increases uPAR expression has not been elucidated. However, it is possible that the mitogen-activated protein kinase pathway is involved, and that downstream targets involve transcription factors and activator proteins that bind to the promotor region of the uPAR gene (34) . In addition, activation of uPAR by ligand binding may initiate a positive feedback loop on its own expression, as activation of Src kinases has been found to result in increased transcription of the uPAR gene (35) .
We found endothelial cell migration to be stimulated mostly by endometrial tissue samples taken in the early to midproliferative phase and the mid to late secretory phase. Samples taken at midcycle, i.e. the late proliferative and early secretory phases, had a much lower stimulatory effect. This pattern of angiogenic activity was also found by Ferenczy et al., who studied uptake of radiolabeled thymidine by endometrial tissue in vitro (36) . These researchers found a higher uptake by endothelial cells of the functional endometrium in the early to midproliferative and the mid to late secretory phases and a lower uptake at midcycle. Rogers et al. (37) , studying migration of endothelial cells in response to endometrial tissue, had a similar finding, although these researchers found an additional peak in the mid/late proliferative phase. Differences between their findings and ours may relate to their use of bovine aortic endothelial cells and a semiquantitative technique. However, in an immunohistochemical study of proliferating cell nuclear antigen expression in endometrial endothelial cells Goodger et al. found no cyclic variation (38) . Using the chorioallantoic membrane assay, Peek et al. found no significant variation over the cycle in the angiogenic signal released from endometrial explants (39) . These conflicting results may reflect differences in study design and assay systems.
The early proliferative peak of angiogenic activity noted by Ferenczy et al. and Rogers et al. has also been observed morphologically (40) and is further supported by our data. Furthermore, Peek et al. showed that estradiol stimulated proliferation in human decidual endothelial cells (41) . The reduction of explant-induced migration at midcycle may appear difficult to explain, as several reports agree that the endometrial expression of EGF is higher in the late than in the early proliferative phase (5, 6) , and studies in mice have shown that endometrial expression of EGF is induced by estradiol (42) . Also, we found increased signal from endometrial tissue explants, which had been exposed to estradiol. One possible explanation relates to the impact of EGFR, as endometrial expression of EGFR messenger ribonucleic acid is at a peak in the midproliferative phase, and EGFR protein is increased in the late proliferative phase (6, 43, 44) , and autocrine binding of EGF to EGFR in the endometrial cells may reduce the release of EGF to the extracellular fluid. In fact, Taketani and Mizuno found that binding of [ 125 I]EGF to endometrial tissue increased during the proliferative phase to high levels during midcycle and was subsequently very low during the mid to late secretory phase (45) . This pattern of EGF binding is perfectly opposite the pattern found by Ferenzy et al. for endothelial cell proliferation (36) and also to that found in our study for endothelial cell migration and for endometrial release of EGF. These data taken together strongly suggest that autocrine binding of EGF by endometrial cells is a mechanism by which paracrine effects of EGF are regulated.
Another possible explanation involves a negative feedback mechanism induced by EGF. As reported, an additional effect of extracellular signal-regulated kinase 2, which is different from its tyrosine-phosphorylating capacity, is to reduce integrin receptor activity by decreasing its ligand binding affinity (46) . That negative feedback loop, by which activation of the EGFR down-regulates endothelial cell migration at the integrin level, could alternatively explain the decreased migratory signal at midcycle.
A third possible explanation involves a concomitant endometrial release of a cofactor for EGF, provided that this cofactor acts to amplify the response to EGF and has a different cyclic pattern. Support for this possibility comes from our observation that a 1000-fold higher concentration was required for a similar migratory response when EGF was added exogenously compared with the concentration of EGF in endometrial explant-conditioned medium. This cofactor is probably not uPA, because uPA was, in fact, released by the endothelial cells themselves. Hypothetically, the cofactor may activate either a different signaling receptor that subsequently interacts with EGFR (32, 33) or other cell surface components that participate in the assembly of focal adhesion sites.
The second peak, which occurs in the mid and late parts of the secretory phase, may not be related to progesterone per se, as progestagenic steroids, at least in experimental systems, seem to be angiostatic (47) . This is also suggested by our own observation of a slightly decreased stimulatory effect of endometrial tissue explants after preincubation with progesterone. Also, an inhibitor of angiogenesis, thrombospondin-1, is up-regulated by progesterone in the human endometrium and may be responsible for spatial or temporal limitation of angiogenesis (48) . However, endometrial expression of EGF in the secretory phase was particularly prominent in stromal cells surrounding small arteries, an observation that may indicate a functional relationship (5) . Most studies of endometrial EGF and EGFR have not distinguished among the early, mid, and late parts of the secretory phase (5, 6, 44) and are thus not very helpful in understanding the EGF-dependent migratory signal in this part of the cycle. However, Taketani and Mizuno, who assayed binding of [ 125 I]EGF to endometrial tissue day by day during the menstrual cycle, found that binding was very much decreased in the mid to late secretory phase (45) . This potentially allows a greater percentage of EGF to be released in the extracellular fluid. We found that endometrial release of EGF tended to be higher in the mid to late secretory phase than in the midcycle phase. We suggest that this is the most likely mechanism by which endometrial cells modulate the paracrine stimulation of angiogenesis.
A minor part of the migratory signal was not blocked by antibodies to either EGF or uPAR, suggesting that a different cytokine using a different mechanism is involved. We studied VEGF, which is known to occur in the endometrium and have important functions during vasculogenesis (1, 49) , and bFGF, which is also present and is known to stimulate endothelial cell migration (2, 22) . However, our data do not support that these growth factors were released to the medium by endometrial tissue explants, although HMEC-1 mi-gration was sensitive to these agents. If bFGF or VEGF had been released by the endometrial explants and if either of them had been responsible for the residual part of the migratory response, their effects would be expected to be inhibited by both the specific antibody and the uPAR antibody. Thus, we conclude that the remaining part of the migratory signal is caused by an unidentified cytokine, and its response does not involve activation of uPAR.
